High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China.
Measles-mumps-rubellavaccine
Mumps
Seroprevalence
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
02 07 2020
02 07 2020
Historique:
pubmed:
25
1
2020
medline:
22
6
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
During the period of immunization with a single-dose measles-mumps-rubella (MMR) vaccine, which has been available since 2008in China, the incidence of mumps in children aged 2-5 years has been high. The aim of this study was to determine the immunity profile of mumps in children aged 2-5 years as part of the assessment of the MMR vaccination strategy. A cross-sectional survey of IgG antibodies against mumps virus in children aged 2-5 years was performed. Analysis by enzyme-linked immune sorbent assay(ELISA)was performed to measure IgG antibodies against mumps virus in the sera of 2-to5-year-old children who had been vaccinated with at least one dose of MMR vaccine. Mumps outbreaks mainly occurred in kindergarten and primary schools and primarily involved children in kindergarten from 2015-2016 in Jiangsu Province. In total, 4,033 children were surveyed. The overall seroprevalence of mumps antibodies was 79.0% (95% CI:78.4-79.6), and the geometric mean concentration (GMC) was 323.6 mIU/ml (309.0-338.8). Both univariate and multivariate survival analysis of seroprevalence showed that several factors contributed to having significant seroprevalence among the 2-to-5-year-old group ( Children who received a single dose of MMR vaccine in kindergarten, particularly the 2-year-old group in the northern region of Jiangsu Province, China, are at high risk of mumps infection. Our study demonstrates thata single-dose MMR vaccine regimen has a limited effect on controlling mumps, which highlights the benefit of introducing a two-dose MMR vaccine schedule.
Sections du résumé
BACKGROUND
During the period of immunization with a single-dose measles-mumps-rubella (MMR) vaccine, which has been available since 2008in China, the incidence of mumps in children aged 2-5 years has been high. The aim of this study was to determine the immunity profile of mumps in children aged 2-5 years as part of the assessment of the MMR vaccination strategy.
METHODS
A cross-sectional survey of IgG antibodies against mumps virus in children aged 2-5 years was performed. Analysis by enzyme-linked immune sorbent assay(ELISA)was performed to measure IgG antibodies against mumps virus in the sera of 2-to5-year-old children who had been vaccinated with at least one dose of MMR vaccine.
RESULTS
Mumps outbreaks mainly occurred in kindergarten and primary schools and primarily involved children in kindergarten from 2015-2016 in Jiangsu Province. In total, 4,033 children were surveyed. The overall seroprevalence of mumps antibodies was 79.0% (95% CI:78.4-79.6), and the geometric mean concentration (GMC) was 323.6 mIU/ml (309.0-338.8). Both univariate and multivariate survival analysis of seroprevalence showed that several factors contributed to having significant seroprevalence among the 2-to-5-year-old group (
CONCLUSION
Children who received a single dose of MMR vaccine in kindergarten, particularly the 2-year-old group in the northern region of Jiangsu Province, China, are at high risk of mumps infection. Our study demonstrates thata single-dose MMR vaccine regimen has a limited effect on controlling mumps, which highlights the benefit of introducing a two-dose MMR vaccine schedule.
Identifiants
pubmed: 31977281
doi: 10.1080/21645515.2019.1708162
pmc: PMC7482879
doi:
Substances chimiques
Antibodies, Viral
0
Measles-Mumps-Rubella Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1738-1742Références
Vaccine. 2008 Jul 4;26(29-30):3601-7
pubmed: 18539365
J Infect Dis. 2009 May 15;199(10):1457-60
pubmed: 19320590
Vaccine. 2011 May 17;29(22):3878-82
pubmed: 21453788
Epidemiol Infect. 2013 Mar;141(3):651-66
pubmed: 22687578
World J Pediatr. 2015 May;11(2):141-7
pubmed: 25416005
Clin Infect Dis. 2008 Apr 15;46(8):1172-80
pubmed: 18444852
PLoS One. 2013;8(3):e58234
pubmed: 23520497
Nature. 1985 Nov 28-Dec 4;318(6044):323-9
pubmed: 3906406
Balkan Med J. 2013 Mar;30(1):16-8
pubmed: 25207062
J Gen Virol. 2014 May;95(Pt 5):1074-1082
pubmed: 24603524
J Infect Dis. 2008 Apr 1;197(7):950-6
pubmed: 18419470
J Infect Dis. 2008 Jun 15;197(12):1662-8
pubmed: 18419346
Clin Infect Dis. 2017 Oct 1;65(7):1094-1102
pubmed: 28595358
Emerg Infect Dis. 2007 Jan;13(1):12-7
pubmed: 17370510
Sci Transl Med. 2018 Mar 21;10(433):
pubmed: 29563321
J Infect Dis. 2017 Apr 15;215(8):1181-1187
pubmed: 28368471
Sci Rep. 2015 Oct 01;5:14660
pubmed: 26423223
Clin Vaccine Immunol. 2017 Jul 5;24(7):
pubmed: 28490424
Lancet. 2008 Mar 15;371(9616):932-44
pubmed: 18342688
J Clin Virol. 2016 Jan;74:8-12
pubmed: 26630067
Pediatr Emerg Med Pract. 2016 Dec;13(12):1-20
pubmed: 27893360
Vaccine. 2014 Aug 20;32(37):4806-12
pubmed: 25000591
Clin Infect Dis. 2017 Feb 15;64(4):408-412
pubmed: 27927872
Vaccine. 2017 May 25;35(23):3116-3122
pubmed: 28457672
Eur J Pediatr. 2015 Jul;174(7):925-32
pubmed: 25579232
Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Jul 6;50(7):611-4
pubmed: 27412837